Jazz Pharmaceuticals PLC 8-K filings

Jazz Pharmaceuticals will terminate its existing Palo Alto lease in 2025 and move to a new location, maintaining its U.S. operations in California and Pennsylvania.

Jazz Pharmaceuticals' subsidiary, Jazz Investments I Limited, successfully closed a $1 billion private offering of exchangeable senior notes due 2030, including the full exercise of the initial purchasers' option, and repurchased $150 million of its ordinary shares.

Jazz Pharmaceuticals secured a partial injunction against Avadel Pharmaceuticals, restricting the marketing and expansion of Avadel's Lumryz for certain indications, following a patent infringement lawsuit.

Jazz Pharmaceuticals announced a 15% year-over-year revenue increase driven by key growth products and updated its 2024 financial guidance.

Jazz Pharmaceuticals held its 2024 annual general meeting, where shareholders voted on director elections, auditor ratification, executive compensation, and share issuance authority.

Jazz Pharmaceuticals has successfully repriced its existing U.S. dollar term loan, converting it to a new tranche with a reduced interest rate margin.

Catherine Sohn, a director at Jazz Pharmaceuticals, has announced her retirement and will not seek re-election at the company's 2024 annual general meeting.

Jazz Pharmaceuticals announced a 12% year-over-year revenue increase driven by key products and affirmed its 2024 financial guidance.

Jazz Pharmaceuticals announced robust full-year and fourth-quarter 2023 financial results, highlighted by significant revenue growth and provided a positive financial outlook for 2024.

Jazz Pharmaceuticals has appointed Patrick Kennedy to its board of directors, effective March 1, 2024, while Peter Gray will not seek re-election at the 2024 annual meeting.

Jazz Pharmaceuticals has appointed Philip Johnson as its new Executive Vice President and Chief Financial Officer, effective March 1, 2024.

Jazz Pharmaceuticals has successfully repriced its existing U.S. dollar term loans, resulting in a reduction of the applicable interest rate margin.